Considerable evidence suggests that dopamine containing neurons participate in the regulation of certain cognitive processes. In the experimental animal, procedures which attenuate central dopaminergic function have been reported to compromise delayed spatial alternation tasks,1 acquisition of active avoidance2 and maintenance of normal spatial working memory.3 Pharmacological stimulation of the dopamine system, on the other hand, tends to reverse some of these performance deficits.46 In man, dopaminergic hypofunction has been implicated in the pathogenesis of Alzheimer's dementia,7 as well as in certain intellectual deficits occurring in Parkinson's disease. 8 Clinical studies suggest that cognitive deficits in Parkinsonian patients involve mainly memory and learning.9 Specifically, while semantic or knowledge memory, notably context-free general principles, associations and rules'0 is reportedly unimpaired, performance in the realm of episodic memory, notably context-bound knowledge, including information learned in the laboratory,10 may be compromised in untreated Parkinsonian individuals."1 Conversely, although reports of cognitive improvement with levodopa treatment in Parkinsonian patients are equivocal,12"-4 treatment with dopaminomimetics has been reported to improve effortful memory in normal individuals. '5 Notwithstanding these observations, the precise contribution of the dopamine system to defined aspects of human intellectual function remains uncertain. In an attempt to explore this matter, verbal and visuospatial functions were studied in Parkinsonian patients both during levodopa stimulated and unstimulated states.
Methods
Eight patients (five men, three women; mean + SEM age 58 + 4-7 years, range 29-70), with the diagnosis of idiopathic Parkinson's disease and eight normal control subjects (five men, three women, mean + SEM age 59 + 3 1 years, range 30-71), consented to participate in this study after full disclosure of its purpose, risks and potential benefits. Symptoms had been present in the patient group for 2 to 21 years (I 1-+ 2-1) and unmedicated severity ranged from 2 to 4 on the Hoehn and Yahr Scale.16 All patients had received levodopa for I to 12 years (mean 7-9 + 1-6). Each now manifested consistent wearing-off phenomena, characterised by a loss of motor response 2 to 4 hours after levodopa administration. All normal control subjects underwent a routine neurological and neuropsychological evaluation to insure that no significant illness was present.
All study subjects received an extensive assessment of intellectual and memory functions. Psychometric tests of Delayed memory tests did however suggest differences between the on and off periods (table) . Average performance on the Logical Memory and the Paired Associates tasks showed a small, albeit consistent, improvement during the levodopa stimulated state (p < 0.05). For the individual patient, six of eight had a performance increment on the Logical Memory task, while five of eight improved on the Paired Associates test (fig 1) . Analysis of the Paired Associates results revealed essentially identical responses between the on and off states on the first trial and the appearance of differences only on subsequent trials (fig 2) . There was no significant correlation between the motor response to levodopa and the cognitive response as measured by either of these tests. Significant alterations in delayed memory could be documented only on the verbal tasks. The Visual Retention test for visuospatial memory failed to demonstrate any consistent differences (table): four patients improved, one remained unchanged and three deteriorated.
A comparison of cognitive performance patterns in Parkinsonian patients with those in normal controls, revealed significant decrements in the patient group of all those functions showing significant differences between the on and off states (p < 0.01). This held true both for comparison of normals with patients when they were "on" as well as when they were "off' (table). Conversely, with the exception of visual disembedding (Embedded Figures), none of the tasks showing "no differences" between patients' on and off period, evidenced significant performance decrements compared to control scores.
Discussion
The present results support the view that pharmacological activation of the dopamine system can affect intellectual function in patients with Parkinson's disease.13 2425 Individuals with predictable wearing-off phenomena were chosen for study so that periods of levodopa-induced stimulation of central dopaminergic mechanisms could be reliably distinguished from periods in which motor function returned to its untreated state. The on-off states were studied in random order on non-consecutive days, in order to limit the possibility of result contamination due to extraneous factors. The assertion that neuropsychological tests used in this study were essentially unaffected by the patients' motor function, gained some empirical support from the absence of any cor- 6- 5. Recent investigations in the experimental animal further support the concept that the dopamine system might be involved in memory functioning. The dopamine antagonist, haloperidol, reportedly disrupts both working and reference memory for a search task in rats with mesocortical damage.29 Lesioning of rat mesocortical and mesolimbic dopaminergic projections from the A-1O nucleus impaired retention of delayed alternation,1 while catecholamine depletion in the pre-frontal cortex of Rhesus monkeys reduced learning on a similar task, a deficit reversible with administration of levodopa. 4 Moreover, biochemical results suggest that cortical dopamine containing neurons facilitate learning of a delayed alternation task in non-drug treated animals. 30 Observations deriving from this study could have important implications for the treatment of specific cognitive deficits in both Parkinsonian and nonparkinsonian individuals. Clearly, the impact of antiparkinsonian therapy on extrapyramidal motor function is much more impressive than on cognitive performance, a finding which is in agreement with earlier assertions.2426 The profound changes in motor performance probably reflect hypofunction of the nigrostriatal dopaminergic system, while the relatively mild cognitive differences between on and off state might indicate a compromise in the functional integrity of another part of the dopaminergic system, particularly the mesocortical pathway. Indeed, the mesocortical system has been implicated in the pathophysiology of Parkinsonism both by direct biochemical evidence3132 as well as by the indirect neurobehavioural evidence presented here and elsewhere.2427 Taken together, the mesocortical system may well account for certain aspects of the cognitive decline in some Parkinsonian patients, particularly in the delayed recall of newly learned materials. It remains to be determined whether Parkinsonian patients more cognitively impaired than present subjects would derive greater benefit from dopaminomimetic treatment on these delayed memory tasks. Finally, if such therapeutic intervention can ameliorate certain aspects of memory failure in Parkinson's disease, the possibility of mesocortical dopamine system dysfunction in other disorders may merit further investigative attention.
